Biotech Values

[GrthzGd]

Luly very evasive

Luly did make the potency comparison with the ICPT's OCA and target by mid-2015 to select his lead compound that DD mentioned from the JPM presentation.

Other than that, his reply to you struck me a accurate, rather than evasive, description of the difficulty that every drug company goes through in developing a reliable small molecule drug with good shelf life that goes to the right part of the body that doesn't kill people.